PET/CT and MRI Model May Help Stratify Prostate Cancer Risk - Scorecard - MDSpire

PET/CT and MRI Model May Help Stratify Prostate Cancer Risk

Retrospective multicenter radiomics study showed moderate to high discrimination in two small external cohorts

  • By

  • Andrea Surnit

  • May 5, 2026

  • 4 min

Share

Clinical Scorecard: PET/CT and MRI Model May Help Stratify Prostate Cancer Risk

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with suspected prostate cancer undergoing biopsy confirmation.
Care Setting

Key Highlights

  • AUC_explanation

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • F
      • u
      • r
      • t
      • h
      • e
      • r
      • s
      • t
      • u
      • d
      • i
      • e
      • s
      • n
      • e
      • e
      • d
      • e
      • d
      • t
      • o
      • v
      • a
      • l
      • i
      • d
      • a
      • t
      • e
      • m
      • o
      • d
      • e
      • l
      • p
      • e
      • r
      • f
      • o
      • r
      • m
      • a
      • n
      • c
      • e
      • i
      • n
      • d
      • i
      • v
      • e
      • r
      • s
      • e
      • p
      • o
      • p
      • u
      • l
      • a
      • t
      • i
      • o
      • n
      • s
      • ,
      • i
      • n
      • c
      • l
      • u
      • d
      • i
      • n
      • g
      • p
      • r
      • o
      • s
      • p
      • e
      • c
      • t
      • i
      • v
      • e
      • s
      • t
      • u
      • d
      • i
      • e
      • s
      • .

      Risks

        Patient & Prescribing Data

        Model performance varies significantly across different centers and patient demographics.

        Clinical Best Practices

        • additional_note

        References

        Original Source(s)

        PET/CT and MRI Model May Help Stratify Prostate Cancer Risk

        • by Andrea Surnit

        • May 5, 2026

        Related Content

        Radiotherapy plus immunotherapy with or without chemotherapy improves survival in elderly esophageal squamous cell carcinoma: a real-world comorbidity-stratified study

        Neoadjuvant Chemo Did Not Improve Disease-Free Survival

        Phase 3 NeoCol trial adds to mixed evidence as field shifts toward biomarker-guided approaches

        AI Model May Help Decipher Malignant, Benign Breast Lesions on MRI

        Model matches deep-learning accuracy and helps physicians reclassify benign breast lesions.